Sage-547 for the Treatment of Refractory Status Epilepticus

 

 

The MGH Epilepsy Service in conjunction with the MGH Neurologicical Critical Care Unit is conducting a trial entitled "An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy in the Treatment of Adults With Super-Refractory Status Epilepticus". Dr. Eric Rosenthal the Principle Investigator for this study. The main goal is study the safety of Sage-547 in patients in status epilepticus, and to examine the effectiveness of this drug in a group of patients in whom other treatments have failed. . Additional goals are to further characterize the pharmacokinetics of Sage-547 in critically ill patients.

The study offers open label treatment with Sage-547 administered intravenously in the Neurological ICU setting over a 5 day period. During the infusion, attempts to taper and discontinue ongoing anesthetic treatment for recurrent seizures will take place. The ability to successfully discontinue anesthetics is the primary endpoint of the study. This study is registered at ClinTrials.gov, NCT02052739.

Patients being treated for refractory status epilepticus may be accepted in transfer for participation in the study at the request of their treating physicians.

If your feel your patient or a family member might be a candidate for this study, please contact Dr. Rosenthal or Abby Cohen, Study Coordinator to discuss the patient and the trial.


Abigail Cohen
Clinical Research Coordinator, MGH Neurology Critical Care Study Coordinator
Phone: 617 724-2829
Email: ACOHEN18@PARTNERS.ORG

 

Samantha Donovan
Clinical Research Coordinator, MGH Neurology Critical Care Study Coordinator
Phone: 617 643 4617
Email:Email: SRDONOVAN@partners.org